Semaglutide
7 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
7
Ongoing
4
Recruiting
2
Completed
3
Sites
500
Countries
40
Endpoints
102
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 102 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 41 of 102 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
14
6
5
5
4
4
1
1
1
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
7 of 7
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| EVOKE PlusA Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) | Semaglutide Alzheimer’s disease | CDR global 0.5 | Ph 3 | Completed | 498 | Sep 2025 | 4 | |
| EVOKEA Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) | Semaglutide Alzheimer’s disease | CDR global 0.5 | Ph 3 | Completed | 447 | Sep 2025 | 3 | |
| NCT05891496A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease | Semaglutide Alzheimer’s disease | CDR global 0.5 | Ph 3 | Completed | 11 | Aug 2024 | - | results |
| NCT07651319Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease | Aldesleukin, Semaglutide Alzheimer’s disease | Alzheimer's disease | Ph 1/2 | Recruiting | 1 | Jun 2029 | - | |
| NCT06072963COMMETS- Combination MCI Metabolic Syndrome | Insulin, Semaglutide Alzheimer’s disease, MCI / preclinical Alzheimer’s | MoCA ≤27 | Ph 2 | Recruiting | 1 | Dec 2027 | 58 | |
| NCT07135245Improved Treatment and Monitoring of Alzheimer's Disease | Semaglutide Alzheimer’s disease | - | Ph 2 | Not yet recruiting | 0 | Sep 2030 | - | |
| NCT07200622Oral Semaglutide in Patients With Alzheimer's Disease | Semaglutide Alzheimer’s disease | Alzheimer's disease | Ph 2 | Not yet recruiting | 0 | Dec 2027 | - |
Showing 1-7 of 7 trials